Similar articles

• Recent advances in glucokinase activators for the treatment of type 2 diabetes.

  Pal M. Pal M. Drug Discov Today. 2009 Aug;14(15-16):784-92. doi: 10.1016/j.drudis.2009.05.013. Epub 2009 Jun 9. Drug Discov Today. 2009. PMID: 19520181 Review.
• Novel glucokinase activators: a patent review (2008 - 2010).

  Sarabu R, Berthel SJ, Kester RF, Tilley JW. Sarabu R, et al. Expert Opin Ther Pat. 2011 Jan;21(1):13-33. doi: 10.1517/13543776.2011.542413. Epub 2010 Dec 15. Expert Opin Ther Pat. 2011. PMID: 21155690 Review.
• Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.

  Xu J, Lin S, Myers RW, Addona G, Berger JP, Campbell B, Chen HS, Chen Z, Eiermann GJ, Elowe NH, Farrer BT, Feng W, Fu Q, Kats-Kagan R, Kavana M, Malkani S, McMasters DR, Mitra K, Pachanski MJ, Tong X, Trujillo ME, Xu L, Zhang B, Zhang F, Zhang R, Parmee ER. Xu J, et al. Bioorg Med Chem Lett. 2017 May 1;27(9):2069-2073. doi: 10.1016/j.bmcl.2016.10.085. Epub 2016 Oct 31. Bioorg Med Chem Lett. 2017. PMID: 28284804
• Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.

  Park K, Lee BM, Hyun KH, Lee DH, Choi HH, Kim H, Chong W, Kim KB, Nam SY. Park K, et al. Bioorg Med Chem. 2014 Apr 1;22(7):2280-93. doi: 10.1016/j.bmc.2014.02.009. Epub 2014 Feb 17. Bioorg Med Chem. 2014. PMID: 24588963
• [Salicylic acid derivatives as simplified and novel GK small molecule activators].

  Huo LC, Zhang YL, Lei L, Liu SN, Shen ZF, Wang YL, Song HR, Feng ZQ. Huo LC, et al. Yao Xue Xue Bao. 2013 Apr;48(4):514-20. Yao Xue Xue Bao. 2013. PMID: 23833938 Chinese.